Market CapSEK42.8m

Last Close SEK0.83

Acarix, a Swedish company, sells the CE-marked CADScor to enable about half of chest-pain patients with suspected coronary artery disease to be ruled out from further, expensive testing.

More Acarix content >

Investment summary

Acarix has announced that the FDA is reviewing a de novo 510(k) application for its innovative CADScor cardiac diagnostic device. This is important news as it could mean that Acarix might enter the US market by 2021 – although it will need marketing alliances and good reimbursement. Given weak European sales and no update on German reimbursement, accessing the large US market could radically transform the business. Acarix might need US clinical data to ensure that it gains Medicare and insurer reimbursement.

Y/E Dec
Revenue (SEKm)
EPS (öre)
P/E (x)
P/CF (x)
2017A 0.6 (29.5) (30.7) (129.31) N/A N/A
2018A 1.0 (41.0) (42.3) (183.48) N/A N/A
2019E 2.6 (42.0) (43.3) (155.85) N/A N/A
2020E 4.1 (43.3) (44.6) (86.37) N/A N/A
Content on Acarix
Acarix – The de novo beat
Healthcare | Update | 3 January 2020
Acarix - dsc_0951
Acarix – Rights funding completed
Healthcare | Update | 6 November 2019
Acarix - dsc_0951
Acarix – Patch reordering and an emerging US strategy
Healthcare | Update | 27 August 2019
Acarix - dsc_0951
View more
Register to receive research on Acarix as it is published
Share price graph
Balance sheet
Forecast net cash (SEKm) 61.9
Forecast gearing ratio (%) N/A
Price performance
Actual (24.4) (44.8) (75.7)
Relative* (28.2) (52.9) (79.5)
52-week high/low SEK3.4/SEK0.7
*% relative to local index
Key management
Dr Werner Braun Chairman
Per Persson CEO
Christian Lindholm CFO
Claus Bo Vöge Christensen COO and co-founder